{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:12:04Z","timestamp":1793391124268,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005859","name":"Heart Rhythm Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010941","name":"University of Vermont","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020397","name":"Cardiovascular Research Institute of Vermont, Larner College of Medicine, University of Vermont","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.hroo.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T23:03:54Z","timestamp":1701990234000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rationale and design of the PACE HFpEF trial: Physiologic accelerated pacing as a holistic treatment of heart failure with preserved ejection fraction"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-314X","authenticated-orcid":false,"given":"Nicole","family":"Habel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Infeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bernknopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lustgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2023.12.001_bib1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared with atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2023.12.001_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of beta-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hroo.2023.12.001_bib3","article-title":"Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation","volume":"17","author":"Habel","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10.1016\/j.hroo.2023.12.001_bib4","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004311","article-title":"Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction","volume":"10","author":"Runte","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hroo.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure","volume":"111","author":"Borbely","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2023.12.001_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hroo.2023.12.001_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.104.481465","article-title":"Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function","volume":"113","author":"Aurigemma","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2023.12.001_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ejhf.2843","article-title":"Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction","volume":"25","author":"Popovic","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hroo.2023.12.001_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017215","article-title":"Heart rate-induced myocardial Ca(2+) retention and left ventricular volume loss in patients with heart failure with preserved ejection fraction","volume":"9","author":"Silverman","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hroo.2023.12.001_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjcard.2019.07.008","article-title":"Effects of a higher heart rate on quality of life and functional capacity in patients with left ventricular diastolic dysfunction","volume":"124","author":"Wahlberg","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2023.12.001_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hroo.2023.12.001_bib13","doi-asserted-by":"crossref","first-page":"H1031","DOI":"10.1152\/ajpheart.00301.2016","article-title":"Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept","volume":"311","author":"Klein","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.hroo.2023.12.001_bib14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.19102\/icrm.2016.070402","article-title":"Step-wise approach to permanent his bundle pacing","volume":"7","author":"Lustgarten","year":"2016","journal-title":"J Innovations Card Rhythm Manage"},{"key":"10.1016\/j.hroo.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.hrthm.2021.11.015","article-title":"Bachmann bundle potential during atrial lead placement: a case series","volume":"19","author":"Infeld","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2023.12.001_bib17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.hroo.2020.09.004","article-title":"An approach towards individualized lower rate settings for pacemakers","volume":"1","author":"Infeld","year":"2020","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.hroo.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cardfail.2018.06.009","article-title":"Safety and feasibility of a nocturnal heart rate elevation-exploration of a novel treatment concept","volume":"25","author":"Yeshwant","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2023.12.001_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12955-019-1104-2","article-title":"Responsiveness and minimal clinically important difference of the Minnesota living with heart failure questionnaire","volume":"17","author":"Gonzalez-Saenz de Tejada","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.hroo.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1054\/jcaf.2000.9503","article-title":"Preferences for treatment outcomes in patients with heart failure: symptoms versus survival","volume":"6","author":"Stanek","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.hroo.2023.12.001_bib25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib26","first-page":"372","article-title":"Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.hroo.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2023.12.001_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/jgs.14940","article-title":"Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction","volume":"65","author":"Upadhya","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.hroo.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hroo.2023.12.001_bib31","first-page":"1121","article-title":"No-implant interatrial shunt for HFpEF: 6-month outcomes from multicenter pilot feasibility studies","volume":"11","author":"Udelson","year":"2023","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.hroo.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2023.12.001_bib33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.122.059486","article-title":"Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure","volume":"145","author":"Borlaug","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2023.12.001_bib34","first-page":"744","article-title":"Transvenous right greater splanchnic nerve ablation in heart failure and preserved ejection fraction: first-in-human study","volume":"10","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.hroo.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2023.12.001_bib36","first-page":"747","article-title":"Rehabilitation intervention in older patients with acute heart failure with preserved versus reduced ejection fraction","volume":"9","author":"Mentz","year":"2021","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.hroo.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2023.12.001_bib38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2023.0675","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial","volume":"329","author":"Reddy","year":"2023","journal-title":"JAMA"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501823003306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501823003306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:27:11Z","timestamp":1762993631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501823003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2666501823003306"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2023.12.001","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the PACE HFpEF trial: Physiologic accelerated pacing as a holistic treatment of heart failure with preserved ejection fraction","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}